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Short running title: Ileal mucosal healing by IFX in CD 
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Abstract 
Objectives: The aim of this study was to endoscopically evaluate ileal mucosal healing 
during maintenance therapy with infliximab in order to investigate the clinical 
significance of endoscopic examination of ileal lesions in Crohn’s disease patients. 
Methods: This study retrospectively analyzed 54 patients who mainly had active 
ulcers of the ileum on endoscopy at baseline, who were responsive to infliximab 
induction, and who received infliximab maintenance therapy. Mucosal healing was 
defined as no ulcer or only ulcer scar. At the time of follow-up endoscopy after starting 
infliximab, the endoscopic score, mucosal healing, and clinical remission were 
evaluated. On long-term follow-up, the correlations between mucosal healing and 
long-term clinical remission, and between mucosal healing and the need for major 
abdominal surgery, were also evaluated.  
Results: Ileal mucosal healing and complete mucosal healing were significantly 
correlated with clinical remission (p=0.046, p=0.0001, respectively). The rate of 
long-term clinical remission was significantly higher in patients with complete 
mucosal healing (p=0.025). The rate of major abdominal surgery for strictures was 
significantly lower in patients with complete mucosal healing (p=0.044). 
Conclusions: Complete mucosal healing after 1-2 years was a predictive factor for 
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long-term clinical remission up to 4 years after starting infliximab. A lack of complete 
mucosal healing was a predictive factor for major abdominal surgery for strictures. The 
present study suggests that endoscopic evaluation of ileal lesions is useful for 
long-term prognosis of Crohn’s disease patients. 
 
Key words: Crohn’s disease, ileum, infliximab, intestinal mucosa, long-term effects 
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Introduction 
 The efficacy of infliximab (IFX) for active Crohn’s disease (CD) lesions was first 
reported in 1997.
1
 Large-scale clinical studies, such as ACCENT 1 and ACCENT 2, 
later reported the efficacy of IFX in CD intestinal lesions and fistulas.
2, 3 
Clinical 
efficacy and safety have also been reported with IFX maintenance therapy.
4-11 
More 
recently, there has been a focus on mucosal healing (MH) in CD. This is because MH 
is now regarded as a predictive factor of the long-term prognosis of CD patients. In 
patients who achieve MH, subsequent rates of steroid usage, recurrence,
12
 and 
surgery
13
 are decreased.  
 IFX is also promising for improving the long-term prognosis in CD. Decreased 
rates of hospitalization and surgery over both 1-year
14
 and 5-year periods
4
 after starting 
IFX have been reported. In addition, in patients who achieve MH with IFX, decreased 
rates of major abdominal surgery (MAS) and need for hospitalization have been 
reported.
15
 Previous studies have mainly focused on colonic MH, 
10-13,15-19 
but because 
ileal CD and ileocolic CD account for more than 70% of all CD cases 
20,21
, the 
presence of ileal lesions cannot be ignored. However, to date, detailed evaluation of 
ileal MH in CD has seldom been reported.  
The present study is a sub-analysis of 185 CD patients previously reported by Ono et 
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al. in whom IFX maintenance therapy was clinically effective.
22 
Endoscopically 
assessed MH of ileal lesions in CD patients on maintenance IFX was analyzed 
retrospectively. The purpose of this study was to investigate whether subsequent 
long-term clinical remission correlated with the endoscopic findings, and whether 
endoscopic examination of ileal MH is useful during maintenance IFX in CD patients.    
 
Methods 
 This study included 54 CD pati nts who had ileal lesions that were observed by 
endoscopy (double-balloon endoscopy or ileocolonoscopy) before and after start of 
IFX treatment and who were on maintenance therapy. The inclusion criterion was 
active ileal ulcers on baseline evaluation. The exclusion criteria were: 1) incomplete 
endoscopic examination; 2) absent endoscopic examination; 3) clinical follow-up 
duration less than 6 months after the start of IFX; 4) colonic CD or aphthous ulcers; 
and 5) presence of a stoma. Incomplete endoscopic examination was defined as the 
case with a narrow range of ileal endoscopic evaluation. Fig. 1 shows the selection 
process for patients in the study. Of the 248 patients started on IFX therapy at our 
hospital by January 2011, 185 had switched to maintenance therapy.
22 
A total of 131 of 
these 185 patients was excluded due to incomplete endoscopic examination (26), 
absent endoscopic examination (81), no active ileal ulcer on initial endoscopy (5), 
colitis type CD (11), solely aphthoid ulcer type CD (4), and surgically created stoma 
(4).   
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 Table 1 shows the patients’ characteristics. Sixteen patients had ileitis and 38 had 
ileocolitis. The mean Crohn’s disease activity index (CDAI) before starting IFX was 
215.0; most patients had mild to moderate disease. Twenty-eight patients (51.8%) had 
previous intestinal surgery before starting IFX. The most common reason for IFX 
induction was severe intestinal inflammation (luminal) in 43 patients (79.6%). 
Concomitant therapy included 5-aminosalicylic acid (5-ASA) in 39 patients (72.2%), 
immunomodulators such as azathioprine (AZA) or 6-mercaptopurine (6-MP) in 28 
(51.9%), and enteral nutrition in 28 (51.9%) patients.   
 Endoscopy was performed with a double-balloon endoscope (DBE: EN-450P5, 
EN-450T5, Fujifilm Medical, Tokyo, Japan) or a colonoscope (PCF-Q260AI, 
CF-H260AI: Olympus, Tokyo, Japan). For follow-up endoscopy, DBE was used in 35 
patients, and ileocolonoscopy was used in 19 patients. In the 35 patients for whom 
DBE was performed, the median length of insertion was 120 cm (90-315) past the 
ileocecal valve. At our hospital, double-contrast imaging of the small intestine is 
performed prior to endoscopy of patients with Crohn’s disease. Then, based on the 
information obtained, either DBE or ileocolonoscopy is selected. DBE was performed 
for two-thirds of patients with extensive lesions in the ileum, while ileocolonoscopy 
was performed for patients whose lesions were confined to the terminal ileum. The 
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lesions with the most severe inflammation were observed on endoscopy. 
The Fukuoka index was used for measurement of the endoscopic activity index. This 
index was originally composed of 3 parameters (stenosis, polyposis and ulcers).
 16
 In 
this study, the ulcer score and the stenosis score were used as the criteria to evaluate 
the ileal and colonic lesions. With the objective of comparing the present findings with 
those of other reports regarding MH, evaluations using the polyposis score were not 
performed. Ileal lesions included anastomotic sites in the ileum, since 16 of the 17 
patients with anastomotic sites that could be observed had active ulcers. In the ileum, 
the site that was observed to have most severe disease was scored. Colonic lesions 
were scored at each site, and just like the ileum, the most severe score was regarded as 
the activity index. No lesions (0 points) or ulcer scarring (1 point) was defined as 
“mucosal healing (MH),” and scores of 2 to 4 points were defined as “no mucosal 
healing (no-MH).” Complete MH was defined as ileal MH in ileal CD, and as both 
ileal and colonic MH in ileocolonic CD. Severe stenosis was defined as a stenosis 
score of 2 or higher. When endoscopic evaluation of dilatation of the proximal 
intestine was difficult due to stenosis, the evaluation was performed by selective 
contrast imaging from the tip of the endoscope. 
Clinical remission was defined as a CDAI below 150. CDAI was evaluated at the same 
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time as endoscopy was performed. The clinical observation period after starting IFX 
was defined as the interval from the commencement of IFX therapy until the day of 
final clinical observation in patients who continued IFX, until the final day that IFX 
was given in patients who discontinued IFX, and until the day of surgery in patients 
who required intestinal surgery. Duration from starting IFX until follow-up endoscopy 
was 18.7±13.3 (3-82) months. Duration from follow-up endoscopic examination until 
the final clinical observation was 30.0±21.0 (0.3-84) months. Duration of clinical 
follow-up after start of IFX was 45.8±20.6 (9-93) months. 
 The correlation between ileal MH and clinical remission was examined in all 54 
patients. The correlation between colonic MH and clinical remission was evaluated in 
the 38 patients with ileocolic CD, after the 16 patients with ileal CD had been excluded. 
The correlation between complete MH and clinical remission was evaluated in all 54 
patients at the follow-up endoscopy.  
Changes after IFX therapy in the ulcer score, assessed using the Fukuoka index, the 
stenosis score, and the CDAI were investigated. The endoscopic score for the ileum 
was evaluated in all 54 patients. The endoscopic score for the colon was evaluated in 
the 38 patients with ileocolonic type. 
Long-term prognosis was evaluated at the final observation in 41 patients treated 
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with IFX for ≥ 1 year. Long-term clinical remission was also defined on the basis of 
the CDAI. Correlations between MH and the long-term clinical remission rate, and 
between MH and MAS for strictures, were also investigated. 
 Statistical analysis of MH and clinical remission at the follow-up endoscopy was 
performed by Fisher’s exact test, that of changes in CDAI and endoscopic scores was 
performed by Wilcoxon’s test, and that of long-term outcomes was performed by the 
Kaplan-Meier method with the log-rank test using SPSS Statistics 21.0. The data for all 
patients’ characteristics are shown as means ± SD. P-value< 0.05 was accepted as 
significant.  
Results 
1. Mucosal healing and clinical remission at the follow-up endoscopy 
1) Correlation between ileal MH and clinical remission  
In all 54 patients, the proportion of clinical remission was significantly higher in the 
ileal MH group than in the no ileal MH group (79.1% (19/24) vs. 50.0% (15/30), 
p=0.046) (Fig.3A). In 16 patients with ileal type, there was not significant correlation 
between ileal MH and clinical remission. 
2) Correlation between colonic MH and clinical remission  
  The proportion of clinical remission was significantly higher in the colonic MH 
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group than in the no colonic MH group (78.9% (15/19) vs. 31.6% (6/19), p=0.0081) 
(Fig.3B). 
3) Correlation between complete MH and clinical remission  
The proportion of clinical remission was significantly higher in the complete MH 
group than in the incomplete MH group (100% (16/16) vs. 47.4% (18/38), p=0.0001). 
The complete MH rate was 29.6% (16/54) (Fig.3C). 
 
2. Changes in CDAI and endoscopic scores after IFX therapy 
1) Change in CDAI 
The CDAI decreased significantly from 215±92.6 before to 145±101 after IFX therapy 
(P< 0.0001). The clinical remission rate after IFX therapy was 63% (34/54). 
2) Change in the ileal ulcer score 
The ileal ulcer score after IFX therapy was 2.2±1.3, which was significantly reduced 
from the pre-therapy score of 3.2±0.6 (P< 0.0001) (Figure 4A). 
3) Change in the colonic ulcer score 
The colonic ulcer score after IFX therapy was 2.0±1.3, which was significantly reduced 
from the pre-therapy score of 2.8±1.2 (P< 0.0001) (Figure 4B). 
4) Change in the ileal stenosis score 
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The ileal stenosis score after IFX therapy was 1.4±1.2, which was not significantly 
different from the score of 1.3±1.2 prior to IFX therapy (P=0.20). 
3. Long-term prognosis 
1) Correlation between the long-term clinical remission rate on the day of final clinical 
observation and MH at the time of follow-up endoscopy 
The clinical remission rate was higher in the complete MH group than in the 
incomplete MH group, and the log-rank test showed the difference between the two 
groups to be significant (P=0.025) (Fig.5A). The clinical remission rate showed no 
significant difference between the colonic MH group and the no colonic MH group 
(P=0.593) The clinical remission rate showed no significant difference between the 
ileal MH group and the no ileal MH group (P=0.268)  
2) Correlation between MH and MAS for strictures  
The MAS free rate for strictures was higher in the complete MH group than in the 
incomplete MH group, and the log-rank test shows the difference between the two 
groups to be significant (P=0.044) (Fig.5B). The surgical site was the ileum in 5 (71%), 
ileum/ascending colon anastomosis in 1, and ileum/ascending colon in 1 patient. The 
MAS-free rate was higher in the ileal MH group than in the no ileal MH group, and the 
log-rank test showed that the difference between the two groups was significant 
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(P=0.030). The MAS-free rate showed no significant difference between the colonic 
MH group and the no colonic MH group (P=0.717). 
Discussion 
The present study is the first clinical study to investigate the significance of ileal 
MH, and complete MH (MH of both ileal and colonic lesions) during IFX maintenance 
therapy. Ileal MH and complete MH were significantly correlated with clinical 
remission at the follow-up endoscopy. Complete MH correlated significantly with 
long-term clinical remission. In addition, a lack of complete MH was a predictive 
factor for MAS due to strictures.  
 There have been few reports of small intestinal mucosal healing due to IFX, but 
Alkiviadis et al. reported that the only change found to show endoscopically significant 
improvement in patients with Crohn’s disease of the small bowel was the number of 
large ulcers.
23
 Imaeda et al. recently reported that, among CD patients on maintenance 
IFX using balloon-assisted endoscopy and colonoscopy, they could not make any 
comparison because there were no descriptions regarding small intestinal mucosal 
healing.
24
 Following IFX therapy, there was not only improvement in colonic ulcer 
lesions, but also significant improvement in ileal lesions. This appears to be an 
important finding, since there have been no published reports of evaluation of mucosal 
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healing separately for the small and large intestines. It was also found that the ileal 
stenosis score did not show much worsening following IFX therapy.  
 D’Haens et al. reported a strong correlation between post-IFX therapy changes in 
CDEIS and CDAI.
11
 The present study found a strong correlation between complete 
MH and clinical remission at the follow-up endoscopy. Therefore, evaluation for ileal 
MH alone or colonic MH alone is insufficient; ideally, both ileal MH and colonic MH 
should be evaluated. 
 With respect to the long-term prognosis, the clinical relapse rate was low in patients 
who achieved complete MH, and the rate of surgery due to stricture was lower in 
patients who achieved complete MH. Schnitzler et al.
15
 and Baert et al.
18
 reported on 
MH and the subsequent long-term prognosis, but there have been no reports 
concerning the importance of complete MH. Accordingly, we think that our present 
study provides valuable new information.  
In the present study, follow-up endoscopy was performed an average of 18.7 months 
after IFX induction. Since there is no substantial discrepancy compared to the 
large-scale studies
 
reported by Rutgeerts et al. and Baert et al.
10,18
, we believe that 
follow-up endoscopy 1-2 years after starting treatment is appropriate.  
  In previous reports about MH with IFX (Table 2), different endoscopic scores were 
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used to define MH.
 10,15,17-19,24
 Most reports define MH as an absence of ulcerations. 
The CDEIS is an endoscopic score focusing on the ileum and colon. The calculations 
required for assessing the CDEIS score are complicated. On the other hand, the 
Fukuoka index
16 
can assess lesions in the small and large intestine, and the calculations 
are easy. The Fukuoka index ulcer score is similar to a four-point scale
25
, which is a 
simplified index of the SES-CD.
26 
The four-point scale includes both ulcers and 
stenosis, and evaluation may be ambiguous. Therefore evaluation of ileal ulcerations 
using the Fukuoka index is highly significant.  
Ono et al.
22 
reported that concomitant EBD for intestinal strictures reduced the rate 
of surgery. Although IFX promotes the healing of lesions, complications due to 
intestinal strictures have been reported.
27, 28 
We also previously reported worsening of 
intestinal stenosis with MH by IFX induction.
16
 New strictures after IFX induction, as 
identified by double contrast radiography or endoscopy, have been reported in 8% of 
cases.
22
 In the present study, the incidence of small intestinal stenosis was investigated. 
Prior to IFX therapy, severe stenosis of 2 points or greater in the ileum was seen in 
43% (23/54). Following IFX maintenance therapy, development of new stenosis or 
worsening of stenosis was seen in 11% (6/54). The study subjects showed a high rate 
of stenosis, and for that reason, it is impossible to evaluate all small intestinal lesions 
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by DBE by the anal approach, and this is another limitation of the present study. 
 Endoscopic evaluation of MH before the advent of DBE was limited to the part of the 
terminal ileum that could be observed by ileocolonoscopy. DBE is a more advanced 
technique than ileocolonoscopy, which enables observation of the entire small 
intestine.
29 
However, in actual practice, adhesions or strictures of the ileum after 
laparotomy in CD patients can severely limit the range of observation. Manes et al. 
also reported that, for half of the patients, the range from Bauhin’s valve that could be 
observed was 50 cm or less, and that DBE for Crohn’s disease was technically 
difficult.
30
  
 In the initial endoscopic observation, the percentage of patients with an ileal ulcer 
score of 3 points or greater was high (89%, 48/54). The mean ileal ulcer score was 3.2 
points, meaning that there were by no means many patients with mild endoscopic 
severity. In addition, the endoscopic examination was performed on the basis of the 
information gained from small intestinal double-contrast imaging, and it can be said 
that it was possible to endoscopically observe the lesions with the most severe 
inflammation. 
 Many of the initially selected patients were later excluded from this study. In 26 
patients, endoscopy was performed, but the presence of stenosis prevented observation 
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of the deep portion of the small intestine on the adoral side of the stenosis, and the 
observable range was thus insufficient. Eighty-one patients did not consent to 
endoscopic examination. Patients with serious complications at baseline and patients 
who did not respond to IFX therapy were excluded. The study patients were thus 
limited to those who achieved induction of remission and underwent endoscopy. It 
could thus be said that there was a selection bias for well-treated patients. However, the 
activity of the small intestinal lesions was high, and endoscopic observation of these 
lesions generated results that show that it is possible to predict the subsequent clinical 
course. Thus, this study has considerable significance. The present study has other 
limitations, such as being a retrospective, single-center study. In addition, a validated 
endoscopic score was not used.  
 We concluded that, in CD patients on IFX maintenance therapy, complete MH after 
1-2 years was a predictive factor for long-term clinical remission for up to 4 years after 
starting IFX. A lack of complete MH was a predictive factor for MAS for strictures. 
Mucosal healing of ileal lesions was associated with long-term clinical remission after 
infliximab maintenance treatment. The present findings suggest that endoscopic 
evaluation of ileal MH is useful for long-term prognosis of CD patients. 
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Figure legends 
 
Figure 1. Subject selection in the present study. 
IFX, infliximab; CD, Crohn’s disease  
 
Figure 2. Schematic illustration of classification of intestinal lesions as evaluated by 
endoscopy (Fukuoka index)
17
.  
 
For assessment of the ulcer score, absence of a lesion was given 0 points, ulcer 
scarring was scored as 1 point, an open ulcer similar to aphthoid ulcers or a small ulcer 
was scored as 2 points, an open longitudinal ulcer less than 5 mm in transverse 
diameter or shallow and broad irregular ulcer was scored as 3 points, and an open 
longitudinal ulcer 5 mm or more in diameter or a deep and broad, irregular but 
well-demarcated ulcer was scored as 4 points. As for the stenosis score, a luminal 
width of at least half of the normal intestinal tract was given 1 point, a luminal width of 
less than half the normal intestinal tract, but through which an endoscope could be 
advanced, was assigned 2 points, and marked stenosis of the lumen such that an 
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endoscope could not be advanced was assigned 3 points.  
 
Figure 3. The proportion of clinical remissions at the follow-up endoscopy: 
comparison of groups with ileal MH and with no ileal MH (3A), comparison of groups 
with colonic MH and with no colonic MH (3B), and comparison of groups with 
complete and incomplete MH (3C). 
The proportion of clinical remission was significantly higher in the ileal MH group 
compared to the no ileal MH group (79.1% (19/24) vs. 50.0% (15/30)). The proportion 
of clinical remission was significantly higher in the colonic MH group compared to the 
no colonic MH group (78.9% (15/19) vs. 31.6% (6/19)). The proportion of clinical 
remission was significantly higher in the complete MH group compared to the 
incomplete MH group (100% (16/16) vs. 47.4% (18/38)).   
 
Figure 4. Serial changes of scores for ileal ulcer (A), colonic ulcer (B) before and after 
IFX therapy.  
There are significant changes in the ileal ulcer score and colonic ulcer score. 
 
Figure 5A. Correlation between the long-term clinical remission rate, evaluated based 
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on the CDAI on the day of final clinical observation, and complete MH at the time of 
the follow-up endoscopy. 
The clinical remission rate is higher in the complete MH group than in the 
incomplete MH group, and the log-rank test shows the difference between the two 
groups to be significant (P=0.025).  
Figure 5B. Correlation between complete MH and MAS for strictures  
The MAS free rate was higher in the complete MH group than in the incomplete 
MH group, and the log-rank test shows the difference between the two groups to be 
significant (P=0.044). 
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CDEIS: Crohn’s Disease Endoscopic Index of Severity, SES-CD: Simple Endoscopic Score for Crohn’s disease,  	
MH: mucosal healing, IFX: infliximab	
       Author	 Year	
Time to follow-
up endoscopy	
Duration of IFX 
treatment	
Proportion of 
MH (%)	
Endoscopic index	 Definition of MH	
Rutgeerts et al.16	 2006	 13.5	 13.5	 50	 CDEIS	
Absence of mucosal 
ulceration 	
Björkesten et al.17	 2011	 3 and 12 	 12	 45.0%, 90.0	
Mucosal activity 
score	
Mucosal activity score	
Laharie et al.19	 2011	 Not described	 28	 60	 CDEIS, SES-CD	
Absence of mucosal 
ulceration	
Imaeda et al.24	 2013	 > 6 months	 40	 25.6	 Rutgeerts' score	
Rutgeerts' score 0 or 
1	
Schnitzler et al.15	 2009	 6.7	 68.7	 45.4	
Original activity 
index	
Complete mucosal 
healing	
Baert et al.18	 2010	 24	 48	 72	 SES-CD	 SES-CD 0	
Present study	 2013	 18.7	 46	 29.6	 Fukuoka index	 Fukuoka index 0 or 1	
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